SEOVF - Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List
(TheNewswire)
Sernova awarded top performer status for two years standing
LONDON, ONTARIO – February 24, 2022 – Sernova Corp.(TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stageregenerative medicine and cell therapy therapeutics company focused ondeveloping a potential ‘functional cure’ for type 1 diabetes (T1D)and other chronic diseases, is pleased to announce that that ithas been named as one of the top 50 performers on the TSX VentureExchange.
The 2022 TSX Venture Top 50 is a ranking of topperformers on the TSX Venture Exchange over the last year based onthree equally weighted criteria: share price appreciation, averagetrading volume and market capitalization growth.
“We are honored by the TSX Venture Exchangerecognition of Sernova as a 2022 Top 50 recipient company. Beingawarded this title two years in a row is strong validation of ourpersistent dedication to increasing shareholder value as we continueto deliver on our strategic plan to build a leadership position in theregenerative medicine cell therapy therapeutics field. In 2022, welook forward to driving continued success through, evolving our clinical programs, further developing ourpharmaceutical partnerships and by advancing our capital marketinitiatives ,” said Dr. Philip Toleikis, ChiefExecutive Officer of Sernova.
As part of the award, the TSX Venture Exchangesponsored a Q&A highlight interview with Dr. Toleikis. To view thevideo, please https://share.vidyard.com/watch/dsfSgoQyYi87x8pj8oUEz6
and for the complete list of 2022 TSX Venture 50companies.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeuticsolutions using a medical device (Cell Pouch) and immune protectedtherapeutic cells / tissues (i.e. human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has beenshown to provide long-term safety and efficacy in small and largeanimal models of diabetes and has been proven to provide abiologically compatible environment for insulin-producing cells inhumans in a Canadian first-in-human study. Sernova is currentlyconducting a Phase I/II study at the University of Chicago. Positiveinitial results have been presented at several internationalscientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Tel: 212-915-2577
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events and are based on information currentlyavailable to management on the date such statements were made. Manyfactors could cause Sernova’s actual results, performances orachievements to not be as anticipated, estimated or intended or todiffer materially from those expressed or implied by theforward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2022 TheNewswire - All rights reserved.